Tenofovir continues to suppresses hepatitis B virus for eight years

postato in: Senza categoria | 0

Most people with chronic hepatitis B who are
treated with tenofovir for eight years continued to maintain viral suppression,
researchers reported at the American
Association for the Study of Liver Diseases (AASLD) Liver Meeting earlier this month in
Boston, United States. Serological response rates continued to increase
over time and kidney and bone-related side-effects remained

Venticinque App per la lotta contro l’Aids

postato in: Senza categoria | 0

Nella Giornata mondiale contro Aids, Apple lancia una campagna di sostegno all’iniziativa ‘Red’ del cantante Bono. Disponibili 25 app tra le più popolari, il cui ricavato sarà devoluto al Fondo globale per la lotta contro la malattia.

Nella Giornata mondiale contro Aids, Apple lancia una campagna di sostegno all’iniziativa ‘Red’ del cantante Bono. Disponibili 25 app tra le più popolari, il cui ricavato sarà devoluto al Fondo globale per la lotta contro la malattia – See more at: http://www.rainews.it/dl/rainews/articoli/25-app-per-la-raccolta-fondi-di-Bono-contro-aids-8fe13e0b-ff56-489f-8bc6-1fc2438099a6.html?refresh_ce#sthash.cm3mycBi.dpuf
Nella Giornata mondiale contro Aids, Apple lancia una campagna di sostegno all’iniziativa ‘Red’ del cantante Bono. Disponibili 25 app tra le più popolari, il cui ricavato sarà devoluto al Fondo globale per la lotta contro la malattia – See more at: http://www.rainews.it/dl/rainews/articoli/25-app-per-la-raccolta-fondi-di-Bono-contro-aids-8fe13e0b-ff56-489f-8bc6-1fc2438099a6.html?refresh_ce#sthash.cm3mycBi.dpuf

Positive response to ‘gift tokens for undetectable viral load’ trial

postato in: Senza categoria | 0

A US study
presented at last month’s HIV Research for Prevention conference found generally
positive responses among people with HIV and clinic staff to a trial that used
$70 gift tokens as an incentive for people to attend clinic regularly,
refill their HIV treatment drug prescriptions, and maintain an undetectable viral load.
However, the
study found

Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients

postato in: Senza categoria | 0

 
A 12-week oral combination
of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high
sustained virological response rates for people with difficult-to-treat HCV
genotype 3 and other genotypes, according to phase 2 study findings presented at
the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting last week in Boston. Reducing treatment duration

1 2 3 4 5 6 8